A single-Arm Phase II Study of Tivantinib (ARQ 197) plus Cetuximab in EGFR inhibitor-resistant MET high subjects with locally advanced or metastatic colorectal cancer with wild-type KRAS
Phase of Trial: Phase II
Latest Information Update: 17 Dec 2018
Price : $35 *
At a glance
- Drugs Tivantinib (Primary) ; Cetuximab
- Indications Colorectal cancer
- Focus Therapeutic Use
- 12 Dec 2018 Status changed from active, no longer recruiting to completed.
- 31 Aug 2018 Biomarkers information updated
- 15 Feb 2016 Planned End Date changed from 1 Jun 2015 to 1 Mar 2017 as reported by ClinicalTrials.gov.